Anti-GD2 chimeric antigen receptor T cell therapy(Yake Biotechnology)

N/A

Report date: 2024/11/13 20:00:43

Base Information

Drug NameAnti-GD2 chimeric antigen receptor T cell therapy(Yake Biotechnology)
Drug Alias NameCAR-T GD-2
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-GD2
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSolid tumoursNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A